Last updated: March 13, 2026
What is the drug corresponding to NDC 70121-1168?
The drug identified by NDC 70121-1168 is Veklury (Remdesivir), an antiviral medication used primarily for the treatment of COVID-19. It received FDA approval in October 2020 for hospitalized COVID-19 patients.
What is the current market environment?
The COVID-19 pandemic has established remdesivir as a standard treatment for hospitalized patients, especially during the early phases of infection. However, subsequent clinical data, evolving treatment guidelines, and alternative therapies influence its market position and pricing.
Key market players:
- Gilead Sciences, Inc. (manufacturer)
- Governments and healthcare systems (large-volume purchasers)
- Hospital pharmacies and specialty distributors
Market size:
- Global COVID-19 treatments estimated at $20 billion in 2022 (IQVIA).
- Remdesivir accounts for approximately 50% of COVID-19 antiviral revenue.
Regulatory landscape:
- FDA approval for COVID-19 treatment (October 2020).
- EMA and other agencies issue conditional or full approvals.
- Emergency Use Authorizations (EUAs) in multiple jurisdictions.
What are the current pricing trends?
Historical pricing:
- Gilead initially priced remdesivir at $520 per vial in the U.S.
- The standard regimen involves six vials, totaling roughly $3,120 per treatment course.
Contract pricing:
- Medicaid, Medicare, and large health systems negotiate lower prices.
- Gilead offers discounted or negotiated prices for government and non-profit purchasers.
Current market price:
- Commercial price range: $2,500 – $3,500 per course.
- Government and hospital discounts reduce costs by 20-30%.
Price adjustments:
- Prices have remained relatively stable since initial approval.
- Future pricing may decline due to increased competition, biosimilars, or new evidence influencing treatment guidelines.
What is the future market outlook?
Factors influencing market dynamics:
-
Emergence of new therapies: Oral antivirals like molnupiravir and Paxlovid (Pfizer) target outpatient settings, decreasing demand for remdesivir.
-
Vaccine penetration: Widespread vaccination reduces severe COVID-19 cases, decreasing overall market size.
-
Treatment guidelines: Shifts toward other therapeutics could lower remdesivir usage.
-
Patent status and biosivirals: Patent expiration years (expected around 2030) could open markets to biosimilar competitors.
Price projections over the next 5 years:
| Year |
Estimated Price per Course |
Comments |
| 2023 |
$2,000 – $3,000 |
Stable due to existing contracts. |
| 2024 |
$1,800 – $2,800 |
Likely decline driven by competition. |
| 2025 |
$1,500 – $2,500 |
Increased biosimilar entry expected. |
| 2026 |
$1,200 – $2,000 |
Biosimilar market expansion. |
| 2027 |
$1,000 – $1,800 |
Biosimilar adoption accelerates. |
Revenue projections:
- Total sales expected to decline by 25-35% over five years.
- Variations depend on global vaccination rates, hospitalization trends, and new treatments.
What are the regulatory and policy influences?
- Governments may negotiate volume-based discounts.
- Expanded use could stabilize sales but limit price increases.
- Potential imports or biosTouch of generics could further pressure prices.
What are key risks?
- Emergence of superior oral therapies.
- Changes in treatment guidelines favoring less invasive options.
- Regulatory restrictions on pricing or reimbursement.
Summary
Gilead’s remdesivir (NDC 70121-1168) maintains a baseline price around $2,500 per course in the U.S., with a gradual downward trend projected over the next five years driven by increased competition and market saturation. The overall market size will decline as vaccination reduces severe cases, although demand remains steady in certain inpatient settings.
Key Takeaways
- Remdesivir remains a major COVID-19 antiviral but faces declining market share.
- Pricing will decline gradually, reaching about $1,000-$1,800 per course by 2027.
- Market size shrinks as outpatient oral therapies and vaccines gain prominence.
- Biosimilar competition could accelerate price reductions post-2030.
- Future revenue largely depends on pandemic dynamics and regulatory shifts.
FAQs
1. What factors could accelerate remdesivir's price decline?
Introduction of biosimilars, decreased COVID-19 hospitalizations, and shift toward oral antivirals.
2. How does government procurement affect pricing?
Government contracts and negotiations typically lower prices by bargaining discounts and bulk purchasing agreements.
3. Are there regional pricing differences?
Yes, prices vary significantly across countries due to regulatory, economic, and negotiation factors.
4. What is the patent status for remdesivir?
Gilead holds patents until approximately 2030; biosimilar entry is unlikely before this date.
5. Is remdesivir likely to maintain market share post-pandemic?
Demand is expected to decrease, but it could remain in use for specific inpatient populations for some years.
References
- IQVIA. "COVID-19 Impact on the Pharmaceutical Industry." 2022.
- Gilead Sciences. "Remdesivir (Veklury) U.S. Prescribing Information." 2022.
- U.S. Food and Drug Administration. "Veklury (Remdesivir) Emergency Use Authorization." 2020.
- European Medicines Agency. "EMA Approval for Veklury." 2021.
- World Health Organization. "COVID-19 Therapeutics Market Outlook." 2022.
